Akari Therapeutics, Plc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
AKTX Nasdaq 2836 www.akaritx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akari Therapeutics, Plc

Akari Therapeutics Announces Key Leadership Appointments - Dec 18th, 2024 1:51 pm
Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer - Dec 16th, 2024 2:05 pm
Akari Therapeutics Regains Full Nasdaq Compliance - Nov 19th, 2024 1:00 pm
This Akari Therapeutics Insider Increased Their Holding By 69% Last Year - Nov 15th, 2024 1:39 pm
Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio - Nov 14th, 2024 9:15 pm
Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger - Nov 8th, 2024 1:00 pm
Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger - Oct 15th, 2024 12:00 pm
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics - Sep 17th, 2024 12:00 pm
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights - Aug 19th, 2024 8:15 pm
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy - Aug 19th, 2024 12:00 pm
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders - Jun 5th, 2024 12:00 pm
Akari Therapeutics Secures $7.6 Million in Upsized Financing Round - Jun 4th, 2024 12:00 pm
Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights - May 16th, 2024 12:00 pm
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics - May 1st, 2024 12:01 pm
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity - May 1st, 2024 12:00 pm
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 - Apr 15th, 2024 12:00 pm
Akari Therapeutics Insider Ups Holding By 69% During Year - Apr 1st, 2024 5:13 pm
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights - Apr 1st, 2024 10:30 am
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit - Mar 5th, 2024 1:00 pm